Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,320 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06943755RecruitingPhase 2/Phase 3
Zanzalintinib vs Everolimus for Neuroendocrine Tumors
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
Birmingham, AlabamaAges 18 years+ - NCT05679674Recruiting
Radiation plus at-home tumor device for locally advanced pancreatic cancer
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
Miami, FloridaAges 18 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07189195RecruitingPhase 1
TR-002 for advanced solid tumors and pancreatic cancer
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07035249RecruitingPhase 1/Phase 2
DCSZ11 plus standard therapy for advanced solid tumors
This trial tests a new drug called DCSZ11 combined with usual chemotherapy and immunotherapy for people with advanced or metastatic solid tumors. It aims to see if adding DCSZ11 works better than standard treatments alone.
Chengdu, SichuanAges 18 years+ - NCT07021898RecruitingPhase 1
ERAS-4001 for advanced solid tumors with mutations
This trial tests a new oral drug called ERAS-4001 for people with advanced solid tumors that have a specific genetic change and are no longer helped by standard treatments. It aims to see if the drug is safe and can shrink tumors.
Nashville, TennesseeAges 18–99 - NCT06983743RecruitingPhase 1
ERAS-0015 for Advanced Solid Tumors With RAS Mutations
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
Santa Rosa, CaliforniaAges 18–99 - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT04353375RecruitingPhase 2/Phase 3
Study drug for FGFR2-mutated bile duct cancer
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT02332668RecruitingPhase 1/Phase 2
Pembrolizumab for children with advanced, hard-to-treat cancer
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
Aurora, ColoradoAges 6 months–17 years - NCT05366478RecruitingPhase 1
LM103 for advanced solid tumors using donated immune cells
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
TianjinAges 18 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT05487170RecruitingPhase 1/Phase 2
Early trial of RNK05047 for advanced cancers
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
Atlanta, GeorgiaAges 18 years+ - NCT06795815Recruiting
Using the Go Wish Game for Future Care Planning
This trial tests a game called 'Go Wish' that helps people with serious cancer think about and talk about their future care wishes. It's designed to help you plan ahead with your care team.
Reggio EmiliaAges 18–99 - NCT06760819RecruitingPhase 2
Sevacertinib for solid tumors with HER2 mutations
This study tests an oral tablet called sevacertinib in people with solid tumors (not lung cancer) that have a HER2 mutation. It aims to see how well the drug works and how safe it is for people who have tried other treatments or have no good options left.
Birmingham, AlabamaAges 18 years+ - NCT06659341RecruitingPhase 1
Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Albury, New South WalesAges 18 years+ - NCT02333110Recruiting
Grid radiation therapy for advanced, painful tumors
This trial tests a way of giving palliative radiation using a “grid” to treat advanced tumors that are large, resistant to standard radiation, or already needed more than one palliative radiation session. It may help better control symptoms when a cure is not the goal.
Montreal, QuebecAges 18 years+ - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT03454035RecruitingPhase 1
Combination of two study drugs for advanced pancreatic and other solid tumors
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Chapel Hill, North CarolinaAges 18–99 - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,320 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.